Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 2
2013 1
2016 2
2017 1
2018 1
2020 3
2021 8
2022 9
2023 10
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
MOG Antibody-Associated Disease in the Setting of Metastatic Melanoma Complicated by Immune Checkpoint Inhibitor Use.
Syc-Mazurek SB, Zhao-Fleming H, Guo Y, Tisavipat N, Chen JJ, Zekeridou A, Kournoutas I, Orme JJ, Block MS, Lucchinetti CF, Mustafa R, Flanagan EP. Syc-Mazurek SB, et al. Among authors: orme jj. Neurol Neuroimmunol Neuroinflamm. 2024 Jul;11(4):e200249. doi: 10.1212/NXI.0000000000200249. Epub 2024 May 2. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 38696737 Free article.
Theranostics and artificial intelligence: new frontiers in personalized medicine.
Belge Bilgin G, Bilgin C, Burkett BJ, Orme JJ, Childs DS, Thorpe MP, Halfdanarson TR, Johnson GB, Kendi AT, Sartor O. Belge Bilgin G, et al. Among authors: orme jj. Theranostics. 2024 Mar 25;14(6):2367-2378. doi: 10.7150/thno.94788. eCollection 2024. Theranostics. 2024. PMID: 38646652 Free PMC article. Review.
Patient-derived tumor xenograft study with CDK4/6 inhibitor plus AKT inhibitor for the management of metastatic castration-resistant prostate cancer.
Kase AM, Gleba J, Miller JL, Miller E, Petit J, Barrett MT, Zhou Y, Parent EE, Cai H, Knight JA, Orme J, Reynolds J, Durham WF, Metz TM, Meurice N, Edenfield B, Alasonyalilar Demirer A, Bilgili A, Hickman PG, Pawlush ML, Marlow L, Wickland DP, Tan W, Copland JA. Kase AM, et al. Among authors: orme j. Mol Cancer Ther. 2024 Mar 6. doi: 10.1158/1535-7163.MCT-23-0296. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38442920
Low PSA radiographic disease progression on C11-choline PET.
Mahmoud AM, Ahmed ME, Kendi AT, Thorpe M, Johnson GB, Riaz IB, Orme JJ, Kwon ED, Andrews JR, Childs DS. Mahmoud AM, et al. Among authors: orme jj. BJUI Compass. 2023 Oct 25;5(2):319-324. doi: 10.1002/bco2.308. eCollection 2024 Mar. BJUI Compass. 2023. PMID: 38371200 Free PMC article.
A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis.
Mosalem O, Tan W, Bryce AH, Dronca RS, Childs DS, Pagliaro LC, Orme JJ, Kase AM. Mosalem O, et al. Among authors: orme jj. Prostate Cancer Prostatic Dis. 2024 Feb 10. doi: 10.1038/s41391-024-00799-y. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38341460
The yin and yang of chromosomal instability in prostate cancer.
Carceles-Cordon M, Orme JJ, Domingo-Domenech J, Rodriguez-Bravo V. Carceles-Cordon M, et al. Among authors: orme jj. Nat Rev Urol. 2024 Feb 2. doi: 10.1038/s41585-023-00845-9. Online ahead of print. Nat Rev Urol. 2024. PMID: 38307951 Review.
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
Orme JJ, Taza F, De Sarkar N, Tewari AK, Arsalan Naqvi S, Riaz IB, Childs DS, Omar N, Adra N, Ashkar R, Cheng HH, Schweizer MT, Sokolova AO, Agarwal N, Barata P, Sartor O, Bastos D, Smaletz O, Berchuck JE, McClure H, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Mehra N, Nelson PS, Hwang J, Dehm SM, Shi Q, Fleischmann Z, Sokol ES, Elliott A, Huang H, Bryce A, Marshall CH, Antonarakis ES. Orme JJ, et al. Eur Urol Oncol. 2023 Dec 9:S2588-9311(23)00277-8. doi: 10.1016/j.euo.2023.11.014. Online ahead of print. Eur Urol Oncol. 2023. PMID: 38072760
44 results